000293348 001__ 293348
000293348 005__ 20241113131935.0
000293348 0247_ $$2doi$$a10.1186/s12879-024-09827-7
000293348 0247_ $$2pmid$$apmid:39300354
000293348 0247_ $$2altmetric$$aaltmetric:168387634
000293348 037__ $$aDKFZ-2024-01894
000293348 041__ $$aEnglish
000293348 082__ $$a610
000293348 1001_ $$aLiang, Linda A$$b0
000293348 245__ $$aPopulation-based age- and type-specific prevalence of human papillomavirus among non-vaccinated women aged 30 years and above in Germany.
000293348 260__ $$aHeidelberg$$bSpringer$$c2024
000293348 3367_ $$2DRIVER$$aarticle
000293348 3367_ $$2DataCite$$aOutput Types/Journal article
000293348 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1727094362_27748
000293348 3367_ $$2BibTeX$$aARTICLE
000293348 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000293348 3367_ $$00$$2EndNote$$aJournal Article
000293348 520__ $$aA persisting high-risk human papillomavirus (HR-HPV) infection is causal for cervical cancer; however, there is limited population-based data on the prevalence of HPV infections in Germany. We assessed the age and type-specific HPV prevalence, and associated risk factors in HPV unvaccinated women aged 30 and above.The MARZY prospective population-based cohort study was conducted between 2005 and 2012 in Mainz and Mainz-Bingen, Germany. Eligible women were randomly recruited from population registries and invited for cervical cancer screening (n = 5,275). A study swab (liquid-based cytology) was taken and HPV testing was performed with GP5+/6 + polymerase chain reaction (PCR) followed by genotyping. We assessed HPV types as HR-HPV, 'moderate' risk and low-risk (LR-HPV). Logistic regression was performed to identify factors associated with HPV infection, stratified by HPV types.2,520 women were screened with a valid PCR result. Overall HPV prevalence was 10.6% (n = 266), with 6.5% HR-HPV positive (n = 165), 1.5% 'moderate' risk type (n = 38) and 3.3% LR-HPV type (n = 84) positive. 8.9% had a single infection (n = 225) and 1.6% had multiple types (n = 41). The most common HR-HPV types were 16, 56, 52 and 31 and LR-HPV 90 and 42. Of 187 HR-HPV infections detected (among 165 women), 55.1% (n = 103) were with HPV types not covered by available bivalent or quadrivalent HPV vaccines. About 23% (n = 43) were of types not covered by the nonavalent vaccine (HPV 35, 39, 51, 56, 59). The HR and LR-HPV prevalence were highest in the age group 30-34 years (HR 9.8%, 'moderate' risk 3.0% and LR 5.6%), decreasing with increasing age. HR-HPV prevalence in women with normal cytology was 5.5%. In women with a high-grade squamous intraepithelial lesion (HSIL), prevalence was 66.7%. Women currently not living with a partner and current smokers had increased chances of an HR-HPV infection.The overall population-based HPV prevalence was relatively high. An important share of prevalent HR-HPV infections constituted types not covered by current HPV vaccines. With the advent of HPV screening and younger vaccinated cohorts joining screening, HPV types should be monitored closely, also in older women who were not eligible for HPV vaccination.
000293348 536__ $$0G:(DE-HGF)POF4-313$$a313 - Krebsrisikofaktoren und Prävention (POF4-313)$$cPOF4-313$$fPOF IV$$x0
000293348 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
000293348 650_7 $$2Other$$aCervical cancer screening
000293348 650_7 $$2Other$$aGermany
000293348 650_7 $$2Other$$aHuman papillomavirus
000293348 650_7 $$2Other$$aPrevalence
000293348 650_7 $$2Other$$aRisk factors
000293348 650_2 $$2MeSH$$aHumans
000293348 650_2 $$2MeSH$$aFemale
000293348 650_2 $$2MeSH$$aPapillomavirus Infections: epidemiology
000293348 650_2 $$2MeSH$$aPapillomavirus Infections: virology
000293348 650_2 $$2MeSH$$aGermany: epidemiology
000293348 650_2 $$2MeSH$$aAdult
000293348 650_2 $$2MeSH$$aPrevalence
000293348 650_2 $$2MeSH$$aMiddle Aged
000293348 650_2 $$2MeSH$$aPapillomaviridae: genetics
000293348 650_2 $$2MeSH$$aPapillomaviridae: classification
000293348 650_2 $$2MeSH$$aPapillomaviridae: isolation & purification
000293348 650_2 $$2MeSH$$aProspective Studies
000293348 650_2 $$2MeSH$$aRisk Factors
000293348 650_2 $$2MeSH$$aAged
000293348 650_2 $$2MeSH$$aAge Factors
000293348 650_2 $$2MeSH$$aUterine Cervical Neoplasms: epidemiology
000293348 650_2 $$2MeSH$$aUterine Cervical Neoplasms: virology
000293348 650_2 $$2MeSH$$aGenotype
000293348 650_2 $$2MeSH$$aHuman Papillomavirus Viruses
000293348 7001_ $$aTanaka, Luana F$$b1
000293348 7001_ $$aRadde, Kathrin$$b2
000293348 7001_ $$0P:(DE-He78)b2a8c60e0778a1ee75e108de510fdeba$$aBussas, Ulrike$$b3$$udkfz
000293348 7001_ $$aIkenberg, Hans$$b4
000293348 7001_ $$aHeideman, Daniëlle A M$$b5
000293348 7001_ $$aMeijer, Chris J L M$$b6
000293348 7001_ $$aBlettner, Maria$$b7
000293348 7001_ $$aKlug, Stefanie J$$b8
000293348 773__ $$0PERI:(DE-600)2041550-3$$a10.1186/s12879-024-09827-7$$gVol. 24, no. 1, p. 1008$$n1$$p1008$$tBMC infectious diseases$$v24$$x1471-2334$$y2024
000293348 8564_ $$uhttps://inrepo02.dkfz.de/record/293348/files/s12879-024-09827-7.pdf
000293348 8564_ $$uhttps://inrepo02.dkfz.de/record/293348/files/s12879-024-09827-7.pdf?subformat=pdfa$$xpdfa
000293348 909CO $$ooai:inrepo02.dkfz.de:293348$$pVDB
000293348 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)b2a8c60e0778a1ee75e108de510fdeba$$aDeutsches Krebsforschungszentrum$$b3$$kDKFZ
000293348 9131_ $$0G:(DE-HGF)POF4-313$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vKrebsrisikofaktoren und Prävention$$x0
000293348 9141_ $$y2024
000293348 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bBMC INFECT DIS : 2022$$d2023-08-25
000293348 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2023-08-25
000293348 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2023-08-25
000293348 915__ $$0StatID:(DE-HGF)0320$$2StatID$$aDBCoverage$$bPubMed Central$$d2023-08-25
000293348 915__ $$0StatID:(DE-HGF)0501$$2StatID$$aDBCoverage$$bDOAJ Seal$$d2023-05-02T09:05:38Z
000293348 915__ $$0StatID:(DE-HGF)0500$$2StatID$$aDBCoverage$$bDOAJ$$d2023-05-02T09:05:38Z
000293348 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bDOAJ : Open peer review$$d2023-05-02T09:05:38Z
000293348 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2023-08-25
000293348 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2023-08-25
000293348 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2023-08-25
000293348 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2023-08-25
000293348 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2023-08-25
000293348 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2023-08-25
000293348 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5$$d2023-08-25
000293348 915__ $$0StatID:(DE-HGF)0561$$2StatID$$aArticle Processing Charges$$d2023-08-25
000293348 915__ $$0StatID:(DE-HGF)0700$$2StatID$$aFees$$d2023-08-25
000293348 9201_ $$0I:(DE-He78)C120-20160331$$kC120$$lPräventive Onkologie$$x0
000293348 980__ $$ajournal
000293348 980__ $$aVDB
000293348 980__ $$aI:(DE-He78)C120-20160331
000293348 980__ $$aUNRESTRICTED